CONGRESS 2013

HEPATITIS C - Monday, January 14th 2013

  • 08:30 Introduction: Treatment of hepatitis C: the cure - Patrick MARCELLIN (France)
  • 08:50 - 09:20 State of the art lecture - Chairman: Tarik ASSELAH (France)
  • Targets for HCV therapy: clinical applications - Charles RICE (USA)
  • 09:20 Optimal treatment with telaprevir - Ira JACOBSON (USA)
  • 09:35 Optimal treatment with boceprevir - Michael MANNS (Germany)
  • 10:05 Management of side effects - Sam LEE (Canada)
  • 10:20 Round table discussion
  • 10:40 - 11:00 Coffee break
  • 11:00 - 12:30 How to optimize current therapy of non G1 patients - Chairpersons: Mark THURSZ (UK) Jake LIANG (USA)
  • 11:45 Round table discussion
  • 15:15 Round table discussion
  • 15:40 - 16:00 Coffee break
  • 16:00 Best strategies for global HCV eradication - Raymond SCHINAZI (USA - Georgia)
  • 16:15 2nd generation protease inhibitors - David NELSON (USA)
  • 17:00 Round table discussion
  • 17:20 - 17:50 Controversy: F1/F2 patients: treat or wait? - Chairman: Graham FOSTER (UK)
  • 18:00 Ajournement
  • 19:30 Congress dinner

HEPATITIS B - Tuesday, January 15th 2013

  • 08:30 Introduction: HBV: viral control or clinical cure? - Patrick MARCELLIN (France)
  • 08:40 - 10:00 The control of HBV related liver disease - Chairpersons: Henry CHAN (Hong Kong) Antonio CRAXI (Italy)
  • 08:40 Impact of therapy on the outcome of CHB - Yun-Fan LIAW (Taiwan)
  • 08:55 Optimal management of patients with resistance - Fabien ZOULIM (France)
  • 09:25 Round table discussion
  • 10:00 - 10:30 Coffee break
  • 10:30 Why do I treat my patient with a NUC? - Ji Dong JIA (China)
  • 11:00 Round table discussion
  • 12:00 Round table discussion
  • 15:15 Round table discussion
  • 16:00 The role of combination therapy - Jorg PETERSEN (Germany)
  • 16:15 Round table discussion
  • 16:45 Ajournement